Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30 2019 - 4:07PM
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today announced an equity
inducement grant to one new employee consisting of an aggregate of
3,800 stock options. The Compensation Committee of the Board of
Directors approved the grant with an effective date of September
30, 2019. The stock options were granted as an inducement material
to the employee entering into employment with the Company in
accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $1.05 per share and
vest over four years, with 25% of the shares vesting on the
one-year anniversary of the applicable vesting commencement date
and 1/48 of the shares vesting monthly thereafter, subject to the
new employee's continued service relationship with the
Company. The stock options are subject to the terms and
conditions of the Company's 2019 Equity Incentive Plan and a stock
option agreement covering the grant.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving
to deliver cures through controllable cell therapies. The company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T and allogeneic T cell therapies. Bellicum’s lead GoCAR-T®
candidate, BPX-601, is designed to be a more efficacious CAR-T cell
product capable of overriding key immune inhibitory mechanisms.
Bellicum’s rivo-cel product candidate is an allogeneic polyclonal T
cell therapy that has shown promising clinical trial results in
reducing leukemia relapse after a stem cell transplant. More
information can be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors:Robert H. Uhl Managing Director Westwicke IR
858-356-5932 Robert.uhl@westwicke.com
Media: Jim Heins Senior Vice President Westwicke PR
203-682-8251 james.heins@icrinc.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024